Healthcare systems continue to struggle to cope with the demands of the ageing population along with advances in medicine that are costing more, even if this has been offset to some extent by the demise of patented blockbuster drugs. This raises questions about what pharmaceutical companies should be doing if they want to ensure that their new drugs are not seen as a major reason for spiralling healthcare costs. It’s worth taking a look at the UK, where the National Health